Zhang Jinjin, Chen Qian, Du Dingfu, Wu Tong, Wen Jingyi, Wu Meng, Zhang Yan, Yan Wei, Zhou Su, Li Yan, Jin Yan, Luo Aiyue, Wang Shixuan
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Aging (Albany NY). 2019 Jan 23;11(2):817-832. doi: 10.18632/aging.101784.
Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.
衰老已被视为一种可治疗的状况,延缓衰老可预防某些疾病。卵巢衰老是器官衰老的一种特殊类型,是最早衰老的器官,因为与其他器官相比,卵巢自出生起就呈现出加速衰老的态势,其特征是卵巢卵泡数量和质量逐渐下降。卵巢衰老被认为是女性身体衰老的起搏器,它驱动着身体多个器官的衰老。因此,抗卵巢衰老已成为生物医学科学家和制药行业广泛关注的研究课题。在过去几年中,在探索可能的抗卵巢药物或方法方面取得了显著进展,如热量限制模拟物、抗氧化剂、自噬诱导剂等。本综述旨在讨论抗卵巢衰老药理学领域的最新进展,并为更好地理解卵巢衰老的分子机制提供新的见解,这可能为未来卵巢衰老及其相关疾病的预防和治疗提供参考。